Totus Medicines names new president and CEO

16 December 2023

US provider of chemical biology technologies Totus Medicines has announced the appointment of Nassim Usman as president and chief executive.

Neil Dhawan, Totus co-founder, founding CEO and chief scientific officer, will transition into a new role as CSO and head of R&D, where he will continue to oversee the company’s platform, programs, and data.

Before joining Totus Medicines, Dr Usman served as resident, CEO and board member at Catalyst, now Gyre Therapeutics (Nasdaq: GYRE). Dr Usman has an extensive background in C-Suite management (CSO, COO, CEO and principal financial officer), board membership on and venture capital investing (Morgenthaler Ventures) in several private and public companies including Sirna Therapeutics (acquired by Merck & Co) and Principia Biopharma (acquired by Sanofi).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK